{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:34:57Z","timestamp":1787240097695,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>\n                    Hepatitis C virus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS). The efficacy and safety of all\u2010oral direct\u2010acting antiviral (DAA) therapy in HCV\u2010associated MCS (HCV\u2010MCS) is largely unknown. The authors studied case series of patients with HCV\u2010MCS who were treated with sofosbuvir\u2010based regimens and historical controls treated with pegylated interferon and ribavirin in a single health care network. HCV\u2010MCS was defined by circulating cryoglobulin associated with systemic vasculitis symptoms. Renal involvement (n\u2009=\u20097) was established by kidney biopsy (n\u2009=\u20095) or by two or more of the following clinical findings: reduced kidney function, proteinuria, or hematuria with other causes excluded (n\u2009=\u20092). Twelve patients received DAA therapy between December 2013 and September 2014. Median age was 61 years, 58% were male, and 50% had cirrhosis. Median baseline serum creatinine was 0.97 mg\/dL (range 0.7\u20102.47). Four patients received rituximab concurrent with DAA therapy. Sustained virological response rate at 12 weeks (SVR12) was 83% overall. Patients with glomerulonephritis who achieved SVR12 experienced an improvement in serum creatinine and a reduction in proteinuria. Cryoglobulin levels decreased in 89% of patients, with median percent decreasing from 1.5% to 0.5% and completely disappearing in four of nine cases who had cryoglobulins measured after treatment. Serious adverse events were infrequent (17%). In contrast, the historical cohort treated with pegylated interferon and ribavirin experienced only 10% SVR12, with 100% experiencing at least one adverse event and 50% experiencing premature discontinuation due to adverse events.\n                    <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                    : SVR12 rates for sofosbuvir\u2010based DAA regimens in HCV\u2010MCS were 83%, significantly higher than historical controls treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced improvement in renal function, including those not concomitantly treated with immunosuppression. (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2016;63:408\u2013417)\n                  <\/jats:p>","DOI":"10.1002\/hep.28297","type":"journal-article","created":{"date-parts":[[2015,10,17]],"date-time":"2015-10-17T05:17:01Z","timestamp":1445059021000},"page":"408-417","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":229,"title":["Treatment of hepatitis C virus\u2013associated mixed cryoglobulinemia with direct\u2010acting antiviral agents"],"prefix":"10.1097","volume":"63","author":[{"given":"Meghan E.","family":"Sise","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson K.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wisocky","sequence":"additional","affiliation":[{"name":"Liver Center, Gastrointestinal Division, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming V.","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine,Brigham and Women's Hospital,Boston,MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna L.","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Liver Center, Gastrointestinal Division, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Lundquist","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Steele","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thiim","sequence":"additional","affiliation":[{"name":"Liver Center, Gastrointestinal Division, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfred W.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikroo","family":"Hashemi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine,Brigham and Women's Hospital,Boston,MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Y.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"Liver Center, Gastrointestinal Division, Department of Medicine,Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"hep28297-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","article-title":"Hepatitis C and renal disease: an update","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"hep28297-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-117-7-573","article-title":"Hepatitis C virus infection in patients with essential mixed cryoglobulinemia","volume":"117","year":"1992","journal-title":"Ann Intern Med"},{"key":"hep28297-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"hep28297-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"hep28297-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-1172-3-25","article-title":"Mixed cryoglobulinemia","volume":"3","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"hep28297-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long\u2010term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open\u2010label, cohort study","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep28297-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFNalpha\/ribavirin\/protease inhibitor combination in severe hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28297-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.08.052","article-title":"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real\u2010world experience from HCV\u2010TARGET","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28297-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26602","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep28297-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative glomerulonephritis associated with hepatitis C virus infection","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"hep28297-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1046\/j.1523-1755.2003.00022.x","article-title":"Hepatitis C virus\u2013related cryoglobulinemic glomerulonephritis: long\u2010term remission after antiviral therapy","volume":"63","year":"2003","journal-title":"Kidney Int"},{"key":"hep28297-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/j.ajkd.2003.11.020","article-title":"Influence of antiviral therapy in hepatitis C virus\u2013associated cryoglobulinemic MPGN","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"hep28297-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non\u2010responders to pegylated interferon and ribavirin and treatment\u2010naive patients: the COSMOS randomised study","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"hep28297-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"hep28297-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","year":"1995","journal-title":"J Hepatol"},{"key":"hep28297-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1373\/clinchem.2006.070961","article-title":"A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C","volume":"52","year":"2006","journal-title":"Clin Chem"},{"key":"hep28297-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post\u2010treatment with sofosbuvir\u2010containing regimens for hepatitis C virus","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep28297-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","article-title":"Biologic and clinical significance of cryoglobulins. A report of 86 cases","volume":"57","year":"1974","journal-title":"Am J Med"},{"key":"hep28297-bib-0022-20241017","first-page":"128382","article-title":"Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence","volume":"2012","year":"2012","journal-title":"Scientifica (Cairo)"},{"key":"hep28297-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis: a long\u2010term followup study","volume":"54","year":"2006","journal-title":"Arthritis Rheum"},{"key":"hep28297-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","article-title":"Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease","volume":"61","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"hep28297-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus peg\u2010interferon\u2010alpha\/ribavirin compared with peg\u2010interferon\u2010alpha\/ribavirin in hepatitis C\u2013related mixed cryoglobulinemia","volume":"116","year":"2010","journal-title":"Blood"},{"key":"hep28297-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1136\/annrheumdis-2014-206180","article-title":"Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir","volume":"73","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"hep28297-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-007-8019-0","article-title":"Rituximab as a therapeutic tool in severe mixed cryoglobulinemia","volume":"34","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"hep28297-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV\u2010associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids","volume":"45","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"hep28297-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus\u2013associated cryoglobulinemic vasculitis","volume":"64","year":"2012","journal-title":"Arthritis Rheum"},{"key":"hep28297-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2012-202770","article-title":"Peg\u2010IFNalpha\/ribavirin\/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24","volume":"73","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"hep28297-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10067-013-2246-y","article-title":"Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL\u20106 is associated with high serum Th2 chemokine CCL2","volume":"32","year":"2013","journal-title":"Clin Rheumatol"},{"key":"hep28297-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2005-01-0126","article-title":"Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C","volume":"106","year":"2005","journal-title":"Blood"},{"key":"hep28297-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","year":"2013","journal-title":"JAMA"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28297","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201602000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:32:03Z","timestamp":1729193523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201602000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28297","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,11]]},"assertion":[{"value":"2015-03-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}